$ALDX

Rayner's RayOne Galaxy IOLs received FDA approval. Aldeyra plans to appeal FDA's rejection of reproxalap for dry eye disease. Sydnexis' SYD-101 for myopia will be reviewed at an FDA Advisory Committee meeting. Kodiak Sciences reported positive Phase 3 trial results for Zenkuda and KSI-501 in wet AMD. 4D Molecular Therapeutics began a Phase 3 trial for DME treatment with 4D-150. A study found a 16.1% increase in corneal transplants over 10 years, but supply-demand gap remains severe.

Aldeyra Therapeutics (ALDX) shares rose 13.79% after the company announced plans to submit a formal dispute resolution request to the FDA regarding its reproxalap program for dry eye disease. The FDA previously issued a Complete Response Letter citing insufficient evidence of efficacy. The move is seen as company-specific rather than sector-wide.

A pooled analysis of two trials found that reproxalap eye drops reduced dry eye symptoms more than a vehicle drop, with benefits seen in the first week. The most common side effect was irritation at the drop site. The study was funded by Aldeyra Therapeutics and published in Ophthalmology and Therapy.

Aldeyra Therapeutics, Inc. (ALDX) filed an SEC Form 8-K — Other Events. Reproxalap for the Potential Treatment of Dry Eye Disease: Regulatory Update CONFERENCE CALL September 29, 2026 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2026 Exhibit 99.1 Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the

Aldeyra Therapeutics, Inc. (ALDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On July 28, 2026, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) executed a lease agreement (the “Office Lease”) with Bradford Street, L.L.C. (“Bradford Street”) for approximately 4,067 square feet of office space lo

Aldeyra Therapeutics, Inc. (ALDX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001341235 Massachusetts 0001341235 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event report

Brady Todd C (President and CEO) purchased 250,000 shares of Aldeyra Therapeutics, Inc. (ALDX) at $1.67 ($0.42M total) on 2026-06-03.

Aldeyra Therapeutics said it is reviewing FDA feedback on its dry eye drug reproxalap after receiving a CRL. CEO Brady said the FDA cited five trials, with disagreement on three; Aldeyra may use the FDA’s Formal Dispute Resolution process. He estimated any extra dry-eye trials could cost ≤$5M each. Aldeyra reported $65M cash and expects runway into H2 2028.

Aldeyra Therapeutics, Inc. (ALDX) has filed its quarterly earnings report (10-Q) for the period ended March 31, 2026, revealing a net loss of $3.5 million, a significant improvement from $9.9 million in the same period last year due to decreased research and development and general and administrative expenses. The company's cash and cash equivalents stood at $65.0 million, and it anticipates these funds will be sufficient to cover operating expenses and debt obligations into the second half of 2028. Aldeyra is highly reliant on the successful commercialization of reproxalap, currently awaiting potential FDA approval, and acknowledged risks associated with regulatory hurdles, intense competition, and the necessity of securing additional funding for future development and commercialization efforts.

Kirby McInerney LLP reminds investors of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) about the May 29, 2026 deadline to become a lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that Aldeyra failed to disclose inconsistent results from clinical trials of its drug candidate, reproxalap, leading to a significant stock price drop following a Complete Response Letter from the FDA. Investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, are encouraged to contact the firm to discuss their rights.